Skip to content
mapperlab
← Dashboard
Stock

NAGE

NIAGEN BIOSCIENCE, INC.
Latest close $3.705 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
6
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Aug 9, 2024Nov 14, 2024Nov 14, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$2.75$3.70+35%
Citadel Advisors re-entered$3.02$3.70+23%
Millennium Management re-entered$3.02$3.70+23%
D.E. Shaw$7.20$3.70-49%
AQR Capital Management$7.20$3.70-49%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Two Sigma Investments 2× in & out→ $3.65-31%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Niagen Bioscience, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
1
Filings · last 90d
4
Total on file
323
Recent SEC buffer
Most recent
Apr 27, 2026

30d / 90d windows measured from Apr 27, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 323 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · NIAGEN BIOSCIENCE, INC.

Annual figures sourced directly from NIAGEN BIOSCIENCE, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$129.42M
FY2025+30% YoY
Net income
$17.38M
FY2025+103% YoY
EPS (diluted)
$0.2000
FY2025+82% YoY
Free cash flow(?)
$13.5M
FY2025+12% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Niagen Bioscience, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ1 2026Q2 2026$5.26$3.65-31%
Citadel AdvisorsQ4 2025open$6.87$3.70-46%
Two Sigma InvestmentsQ1 2025Q3 2025$5.87$9.71+65%
Millennium ManagementQ1 2025open$5.87$3.70-37%
D.E. ShawQ4 2024open$7.20$3.70-49%
AQR Capital ManagementQ4 2024open$7.20$3.70-49%
Citadel AdvisorsQ3 2024Q3 2025$3.02$9.71+222%
Millennium ManagementQ3 2024Q4 2024$3.02$7.20+138%
Renaissance TechnologiesQ3 2024open$2.75$3.70+35%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.